You're viewing a public preview of this transaction Sign up free to access full investor details, deal amounts & seller data
Sign Up Free Log In
Deal Overview

AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs

Transaction #151327
Investor
1
Sign up to view
Target Company
AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs
Life Science · Austria
Sellers
No seller data
Target Company
Company Sector Entity Type Status State Country
AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs Life Science Private Inactive — Austria
Investors 1
InvestorInvestment TypeAmount% Holding
View 1 Investor
Sign up to access investor names, investment types, deal amounts and ownership percentages
Sign Up Free Log In
Sellers
Seller
View Sellers
Sign up free to access seller names and full exit details for this transaction
Sign Up Free Log In
Frequently Asked Questions
What is the AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs acquisition deal?
This transaction is an acquisition of AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs. The target company operates in the Life Science sector. Full deal details are available on AcquityData.
When did the AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs acquisition happen?
Transaction date information is available on AcquityData.
What is the deal value of the AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs acquisition?
Deal value information for this transaction is available on AcquityData.
Who are the investors in the AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs transaction?
This transaction has 1 investor. Sign up to AcquityData to view investor names, investment types, amounts and ownership details.

Access the full AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs deal profile

Unlock investor names, amounts, seller details and complete M&A intelligence in one connected platform.

Start Free Trial